7,134 Shares in Hologic, Inc. (NASDAQ:HOLX) Bought by Allstate Corp

Allstate Corp acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 7,134 shares of the medical equipment provider's stock, valued at approximately $514,000.

A number of other large investors have also added to or reduced their stakes in the stock. General Partner Inc. bought a new position in shares of Hologic in the fourth quarter worth approximately $26,000. Groupama Asset Managment lifted its position in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Shares of NASDAQ HOLX traded down $0.83 during midday trading on Friday, reaching $60.86. The stock had a trading volume of 6,509,048 shares, compared to its average volume of 1,842,488. The company has a market capitalization of $13.66 billion, a price-to-earnings ratio of 19.20, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12-month low of $59.06 and a 12-month high of $84.67. The stock has a 50-day moving average of $64.30 and a 200-day moving average of $72.52. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Remove Ads

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

HOLX has been the subject of a number of recent analyst reports. William Blair reissued an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Citigroup cut their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada lowered their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Finally, Needham & Company LLC lowered Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective for the company. in a report on Monday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.